Kymera Therapeutics reported positive early‑stage results for KT‑621 in atopic dermatitis, with a Phase 1b BroADen study showing an average 63% reduction in Eczema Area and Severity Index (EASI) after four weeks of treatment. The small, 22‑patient trial delivered an efficacy signal comparable to Dupixent’s effect size in certain measures, raising the prospect of an oral competitor in a high‑value indication. The company has now succeeded in early trials twice this year, underscoring reproducibility of the biomarker and clinical signal. Kymera will need larger, controlled trials to assess durability, safety and how an oral small‑molecule degrader stacks up on key endpoints versus injectable biologics.